US2020397788A1PendingUtilityA1

Par1 modulation to alter myelination

54
Assignee: MAYO FOUND MEDICAL EDUCATION & RESPriority: Jul 7, 2014Filed: Jan 29, 2020Published: Dec 24, 2020
Est. expiryJul 7, 2034(~7.9 yrs left)· nominal 20-yr term from priority
Inventors:Isobel A. ScarisbrickHye-Sook YoonKristen L. Drucker
A61K 35/12C12N 15/85A61K 31/7105A61K 31/519A61K 48/0066C12N 2506/03A61K 35/30C12N 2506/08A61K 48/00A61K 48/0058C12N 15/63C12N 15/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Materials and methods for modulating protease activated receptor 1 (PAR1) activity to alter myelination are provided.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method for modulating myelination in a subject, comprising delivering to the subject a plurality of modified stem cells that have reduced PAR expression as compared to corresponding wild type stem cells. 
     
     
         16 . The method of  claim 15 , wherein the subject is a human. 
     
     
         17 . The method of  claim 16 , wherein the human is an adult with a demyelinating disorder. 
     
     
         18 . The method of  claim 16 , wherein the human is a preterm infant. 
     
     
         19 . The method of  claim 15 , wherein the stem cells are neural stem cells. 
     
     
         20 . The method of  claim 19 , wherein the neural stem cells comprise a mutation in the PAR1 gene. 
     
     
         21 . A method for providing a subject having a demyelinating disorder with modified stem cells, said method comprising delivering to the subject a plurality of modified stem cells that have reduced PAR expression as compared to corresponding wild type stem cells. 
     
     
         22 . The method of  claim 21 , wherein the subject is a human. 
     
     
         23 . The method of  claim 22 , wherein the human is an adult having said demyelinating disorder. 
     
     
         24 . The method of  claim 22 , wherein the human is a preterm infant having said demyelinating disorder. 
     
     
         25 . The method of  claim 21 , wherein the stem cells are neural stem cells. 
     
     
         26 . The method of  claim 25 , wherein the neural stem cells comprise a mutation in the PAR1 gene.

Join the waitlist — get patent alerts

Track US2020397788A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.